Review Library
Longevity · Cluster

NAD+ Injection Protocols: Dosing, Frequency, What to Expect

By Marcus Reed 11 min read Updated June 14, 2026
Disclosure: This article contains affiliate links. If you click through and make a purchase, Healthy Fitness Goal may earn a commission at no extra cost to you. Our editorial opinions are independent and not influenced by affiliate relationships.
The Short Answer · Updated May 2026

Standard NAD+ injection protocols range from 100 mg twice weekly to 500 mg weekly, with most patients in a middle range of 150–300 mg twice weekly.[1] Subcutaneous injection is the most common route — easier, lower-discomfort, and produces sustained NAD+ elevation. Most patients report subjective improvements (energy, sleep, mental clarity) within the first 2–4 weeks, with full effects established over 8–12 weeks.

Protocols should be supervised by a provider familiar with NAD+ therapy because dosing and frequency need adjustment based on individual response. Our editor’s pick for prescription NAD+ in 2026 is HermanRx — competitive pricing with comprehensive medical oversight built into the protocol design.

What this guide covers.

This is a practical implementation guide for patients who have already decided to try NAD+ injection therapy. For background on whether NAD+ injection or oral NMN is right for you, see our companion pillar piece on NAD+ vs NMN. This post focuses on the specifics of injection protocols.

The standard protocol options

There is no single “correct” NAD+ protocol — different practitioners have developed variations based on patient response, cost considerations, and target outcomes. The four most common approaches:

Protocol A: Loading + Maintenance

An initial 4–6 week loading phase of higher frequency injections (200–300 mg three times weekly), followed by a maintenance phase at 1–2 times weekly. The logic is to build tissue NAD+ levels rapidly during loading, then sustain them with less frequent dosing.

Best for: Patients with significant fatigue, recovery issues, or other acute symptoms who want faster subjective response. Typical monthly cost: $400–$600 during loading, $200–$350 during maintenance.

Protocol B: Steady Twice-Weekly

Consistent 150–300 mg subcutaneous injection twice weekly, ongoing. No loading phase. Most common protocol for general longevity-oriented patients.

Best for: Patients prioritizing consistency and predictable cost over rapid response. Typical monthly cost: $249–$349.

Protocol C: Weekly Higher-Dose

A single weekly injection at 400–500 mg. Less injection frequency, larger per-injection dose.

Best for: Patients who prefer fewer injections and don’t mind a slightly higher per-dose discomfort. Typical monthly cost: $200–$300.

Protocol D: Periodic Intensive (IV)

Periodic IV infusion sessions (typically every 4–8 weeks) of 500–1000 mg over several hours, with no daily or weekly maintenance injection. Less common; usually used as a periodic “boost” rather than a primary protocol.

Best for: Patients seeking maximum acute response or who can’t maintain a self-injection routine. Typical cost: $400–$800 per infusion session.

Route of administration: SubQ vs IM vs IV

RouteBioavailabilityConvenienceDiscomfort
Intramuscular~100%ModerateModerate
Intravenous~100%Low · clinic visitHigher initially

All three routes deliver essentially 100% bioavailability — the medication enters circulation directly without first-pass metabolism. The choice is about practical factors: subcutaneous is easiest and most common for ongoing protocols, intramuscular is occasionally used for slightly different absorption kinetics, and intravenous is reserved for periodic intensive sessions.

What to expect across the first 12 weeks

Week 1–2

Initial protocol begins. Some patients report subtle changes within the first few injections — typically improved sleep or modestly higher energy. Others feel nothing yet. Both are normal. A transient flushing or warmth sensation immediately after injection is common and benign.

Week 2–4

Subjective changes become more noticeable for most patients. The most commonly reported are: improved sleep quality (often the earliest change), increased daytime energy, better mental clarity or reduced “brain fog,” and faster recovery from physical exertion. Some patients report mood improvements.

Week 4–8

Steady-state is established. Patients typically have a clear sense by this point of whether the protocol is producing meaningful benefit. If subjective changes are minimal, this is the time to discuss dose adjustment or protocol modification with your provider.

Week 8–12

Full effect window. Lab measurements of blood NAD+ levels (if checking) typically show substantial elevation from baseline. Many patients describe the changes as “settling in” — what initially felt like a noticeable improvement now feels like a new baseline.

At the 12-week mark, most providers do a formal protocol review: assess subjective response, check labs if relevant, and decide whether to continue current protocol, adjust dose, or transition to a maintenance phase.

Editor’s Pick · Prescription NAD+

HermanRx — protocol design with medical oversight.

Provider consultation determines the right protocol for your starting point and goals. Subcutaneous injections from US-licensed 503A pharmacy partners. $249–$349 per month.

Visit HermanRx →

Practical injection guidance

For patients self-administering subcutaneous injections:

Adjusting protocols based on response

The “right” protocol depends on response, not just initial design. Common adjustment scenarios:

The Verdict · Protocol Selection 2026
Start with twice-weekly 150–300 mg. Adjust based on response.

For most patients new to NAD+ injection, the standard twice-weekly subcutaneous protocol (Protocol B) is the right starting point — predictable cost, sustained NAD+ elevation, and easy to adjust based on the 4–8 week response review. Patients with acute symptoms may benefit from a 4–6 week loading phase upfront (Protocol A).

For protocol design and ongoing oversight, HermanRx is our editor’s pick in 2026 — provider consultation determines the right starting protocol, US-licensed 503A pharmacy partners prepare the medication, and adjustments happen through provider review rather than guesswork.

Visit HermanRx.com → Affiliate link · We may earn a commission

Frequently asked questions

Can I use NAD+ injection with NMN supplementation?

Yes. Some patients use both — injection for periodic elevation, oral NMN as a daily baseline. There’s no specific contraindication, though combined cost is significant and the marginal benefit of layering them is debated.

How long should I stay on a NAD+ protocol?

There is no fixed duration. NAD+ levels decline continuously with aging, so the rationale for maintaining elevated levels applies indefinitely. Practically, most patients evaluate response and cost at 6 and 12 months and decide whether to continue at current dose, reduce to maintenance, or discontinue.

Will I become dependent on NAD+ injections?

No. NAD+ is a coenzyme your body produces naturally. Stopping injections returns NAD+ levels to your pre-protocol baseline gradually — no withdrawal, no rebound symptoms. Subjective benefits from the protocol fade as levels normalize, but there is no dependency.

Can I take a break from the protocol?

Yes. Many patients pause for travel, cost reasons, or simply to assess whether the subjective benefits they were attributing to NAD+ persist. Resuming after a break is straightforward — typically restart at the previous protocol without a new loading phase.

Are blood tests required?

Not strictly required, but useful. Baseline NAD+ measurement before starting and a follow-up measurement at 8–12 weeks can confirm that the protocol is achieving the expected elevation. Some patients also monitor inflammatory markers and metabolic panels alongside.

How often is this article updated?

Reviewed quarterly. NAD+ research and protocol practices are evolving. Updates reflect new comparative effectiveness data and provider-practice patterns.

Important. NAD+ injection is a compounded medication that requires a prescription following clinical evaluation. Protocols described here reflect common clinical practice patterns and should not be implemented without provider supervision. NAD+ has not been proven to extend lifespan in humans in long-term randomized trials.

Sources & Citations

  1. Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science.
  2. Yoshino J., et al. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metabolism.
  3. Mills K.F., et al. Long-term administration of NMN mitigates age-associated physiological decline in mice. Cell Metabolism.